A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
BeOne Medicines
Incyte Corporation
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Hoffmann-La Roche
Boundless Bio, Inc.
Novartis
AstraZeneca
LeonaBio
Hoffmann-La Roche
Novartis
Laekna Limited
Novartis
Relay Therapeutics, Inc.
Incyclix Bio
InventisBio Co., Ltd
Eli Lilly and Company
AstraZeneca
Novartis
TransThera Sciences (Nanjing), Inc.
Merck Sharp & Dohme LLC
Terremoto Biosciences Inc.
Hoffmann-La Roche
Ellipses Pharma
Eli Lilly and Company
Hoffmann-La Roche
AstraZeneca
Pfizer
Hoffmann-La Roche
Ensem Therapeutics
Atavistik Bio, Inc
Hoffmann-La Roche
Olema Pharmaceuticals, Inc.
Aminex Therapeutics, Inc.
Genentech, Inc.
Eisai Inc.
BeOne Medicines
Eli Lilly and Company
Novartis
Novartis
Pfizer
Celcuity Inc
Nanjing Chia-tai Tianqing Pharmaceutical
Eli Lilly and Company
Hoffmann-La Roche
Celcuity Inc
Genentech, Inc.
Sermonix Pharmaceuticals Inc.
Eli Lilly and Company